aptaTargets announces positive preliminary data from the ApTOLL Phase 2a clinical trial for stroke
aptaTargets to present ApTOLL at the Oligonucleotide Therapeutics Conference 2022 in United Kingdom
aptaTargets visits Singapore’s healthcare ecosystem with ICEX and MedTech Actuator
aptaTargets presents ApTOLL at the International Oligonucleotides and Peptides Conference 2022
aptaTargets completes recruitment for Phase 2a clinical trial of ApTOLL in stroke
aptaTargets’ Phase 1b clinical data for ApTOLL published in ‘Molecular Therapy: Nucleic Acids’ journal
aptaTargets announces first patient dosed in the clinical trial of ApTOLL for COVID-19
aptaTargets joins a consortium to accelerate RNA-based therapies in Spain
aptaTargets to present new ApTOLL clinical data at the International Stroke Conference 2022
aptaTargets tests an aptamer in COVID-19 patients
CDTI-Cervera program
APRIL trial update: completed enrollment and dosing for Phase 1b
CDTI-PID program
APRIL trial (Acute Ischemic Stroke) gets authorization by the ANSM (France) and the BfArM (Germany)
aptaTargets starts Phase 1b/2a clinical trial with ApTOLL in stroke patients
aptaTargets closes a second round of €5 million
ApTOLL efficacy in myocardial infarction
Authorization to start the APRIL trial
RETOS funding for the ApTOLL stroke program
Torres Quevedo grant
aptaTargets announces completion of enrollment in the Phase I study of ApTOLL in healthy volunteers
EIT Health
First Patient in the ApTOLL-FIH-01 trial: <span class="light">a Phase I trial in healthy volunteers</span>
aptaTargets: finalist award <span class="light">at the EIT Health annual meeting 2018</span>
aptaTargets gets new funding from the RETOS-program <span class="light"> for exploring inflammatory pathologies</span>
RETOS funding for the ApTOLL stroke program
aptaTargets: awarded by Doctorado Industrial Program
EIT Health
aptaTargets gets funds from NEOTEC Program
aptaTargets closes €2.7- million round of funding for new stroke treatment
ApTOLL gets funds from Retos-2015 Program